« FFFT3 Home | Email msg. | Reply to msg. | Post new | Board info. Previous | Home | Next

Exclusive: FDA faults quality control at Lilly plant making Trump-touted COVID drug

By: clo in FFFT3 | Recommend this post (0)
Wed, 14 Oct 20 12:51 PM | 16 view(s)
Boardmark this board | Food For Further Thought 3
Msg. 60889 of 65535
Jump:
Jump to board:
Jump to msg. #

Exclusive: FDA faults quality control at Lilly plant making Trump-touted COVID drug
By Dan Levine, Marisa Taylor

....
But the findings by the U.S. Food and Drug Administration inspectors at the Lilly manufacturing facility, which have not been disclosed previously, could complicate the drugmaker’s bid for a so-called emergency use authorization (EUA) from the federal agency, two of the sources and two outside legal experts told Reuters. That’s because U.S. law generally requires compliance with manufacturing standards for authorization of a drug.

The three sources who spoke to Reuters requested that their names be withheld so they could speak freely without fear of retaliation.

Inspectors who visited the Lilly plant in Branchburg, New Jersey, last November found that data on the plant’s various manufacturing processes had been deleted and not appropriately audited, government inspection documents show.

“The deleted incidents and related audit trail were not reviewed by the quality unit,” the FDA inspectors wrote. Because the government inspection documents reviewed by Reuters were heavily redacted by the FDA it was not possible to see the inspectors’ more specific findings.

Following its November inspection, the FDA classified the problems as the most serious level of violation, resulting in an “Official Action Indicated” (OAI) notice.

That “means that the violations are serious enough and have a significant enough impact on the public health that something needs to be fixed,” said Patricia Zettler, a former associate chief counsel at the FDA who is now a law professor at Ohio State University.

Separately, Lilly said on Tuesday it had paused its clinical trial for the COVID drug in hospitalized patients “out of an abundance of caution” over a potential safety concern. The company did not release information on what the problem was and declined to say how the news might affect their EUA request.

more:
http://www.reuters.com/article/us-health-coronavirus-lilly-exclusive/exclusive-fda-faults-quality-control-at-lilly-plant-making-trump-touted-covid-drug-idUSKBN26Y30C




Avatar

DO SOMETHING!




» You can also:
« FFFT3 Home | Email msg. | Reply to msg. | Post new | Board info. Previous | Home | Next